The Growing Case for Use of SGLT2i in Heart Failure: Additional Benefits of Empagliflozin in a HFpEF Rodent Model.

JACC Basic Transl Sci

Department of Pathology, Division of Molecular and Cellular Pathology, University of Alabama at Birmingham, Birmingham, Alabama.

Published: February 2019

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390674PMC
http://dx.doi.org/10.1016/j.jacbts.2019.01.003DOI Listing

Publication Analysis

Top Keywords

growing case
4
case sglt2i
4
sglt2i heart
4
heart failure
4
failure additional
4
additional benefits
4
benefits empagliflozin
4
empagliflozin hfpef
4
hfpef rodent
4
rodent model
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!